Carbapenem-resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa

Journal of Medical Microbiology

Volumn 62, Issue , 2013, Pages 1317-1325

  Fusté, Ester ^a   López Jiménez, Lídia ^a   Segura, Concha ^b   Gainza, Eusebio ^c   Vinuesa, Teresa ^a   Viñas, Miguel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Laboratorio de Referencia de Catalunya   (Spain)

^c Praxis Pharmaceuticals   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; OUTER MEMBRANE PROTEIN; PORIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BIOASSAY; BLOOD CULTURE; CONTROLLED STUDY; EFFUSION; INTEGRON; MULTIDRUG RESISTANCE; NONHUMAN; OUTER MEMBRANE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; SEROTYPE; SPUTUM CULTURE; SURGICAL WOUND; URINE CULTURE;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BASE SEQUENCE; CARBAPENEMS; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; DIPEPTIDES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PORINS; PSEUDOMONAS AERUGINOSA; THIENAMYCINS; TOBRAMYCIN;

EID: 84881593325     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.058354-0     Document Type: Article

References (40)

1. Azucena, E. & Mobashery, S. (2001). Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition. Drug Resist Updat 4, 106-117.
2. Blumer, J. L., Saiman, L., Konstan, M. W. & Melnick, D. (2005). The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 128, 2336-2346.
3. Cabot, G., Ocampo-Sosa, A. A., Domínguez, M. A., Gago, J. F., Juan, C., Tubau, F., Rodríguez, C., Moyà, B., Peña, C. & other authors (2012). Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 56, 6349-6357.
4. Chen, J., Su, Z., Liu, Y., Wang, S., Dai, X., Li, Y., Peng, S., Shao, Q., Zhang, H. & other authors (2009). Identification and characterization of class 1 integrons among Pseudomonas aeruginosa isolates from patients in Zhenjiang, China. Int J Infect Dis 13, 717-721.
5. CLSI (2010). Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute.
6. Drusano, G. L., Liu, W., Fregeau, C., Kulawy, R. & Louie, A. (2009). Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pumpoverexpressed mutant. Antimicrob Agents Chemother 53, 2266-2273.
7. EUCAST (2011). European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website. http://www.eucast.org
8. Falagas, M. E., Koletsi, P. K. & Bliziotis, I. A. (2006). The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 55, 1619-1629.
9. Farra, A., Islam, S., Strålfors A., Sörberg, M. & Wretlind, B. (2008). Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int J Antimicrob Agents 31, 427-433.
10. Fenosa, A., Fusté, E., Ruiz, L., Veiga-Crespo, P., Vinuesa, T., Guallar, V., Villa, T. G. & Viñas, M. (2009). Role of TolC in Klebsiella oxytoca resistance to antibiotics. J Antimicrob Chemother 63, 668-674.
11. Fonseca, E. L., Vieira, V. V., Cipriano, R. & Vicente, A. C. (2005). Class 1 integrons in Pseudomonas aeruginosa isolates from clinical settings in Amazon region, Brazil. FEMS Immunol Med Microbiol 44, 303-309.
12. Horii, T., Ichiyama, S., Ohta, M. & Kobayashi, M. (1999). Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa. J Med Microbiol 48, 309-315.
13. Ikonomidis, A., Tsakris, A., Kantzanou, M., Spanakis, N., Maniatis, A. N. & Pournaras, S. (2008). Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa. FEMS Microbiol Lett 279, 36-39.
14. Kanj, S. S. & Kanafani, Z. A. (2011). Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum b-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86, 250-259.
15. Koutsogiannou, M., Drougka, E., Liakopoulos, A., Jelastopulu, E., Petinaki, E., Anastassiou, E. D., Spiliopoulou, I. & Christofidou, M. (2013). Spread of multidrug-resistant Pseudomonas aeruginosa clones in a university hospital. J Clin Microbiol 51, 665-668.
16. Kriengkauykiat, J., Porter, E., Lomovskaya, O. & Wong-Beringer, A. (2005). Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49, 565-570.
17. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
18. Lévesque, C., Piché, L., Larose, C. & Roy, P. H. (1995). PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob Agents Chemother 39, 185-191.
19. Llanes, C., Neuwirth, C., El Garch, F., Hocquet, D. & Plésiat, P. (2006). Genetic analysis of a multiresistant strain of Pseudomonas aeruginosa producing PER-1 beta-lactamase. Clin Microbiol Infect 12, 270-278.
20. Lomovskaya, O. & Watkins, W. (2001). Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 3, 225-236.
21. Mao, W., Warren, M. S., Lee, A., Mistry, A. & Lomovskaya, O. (2001). MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45, 2001-2007.
22. Maslow, J. N., Slutsky, A. M. & Arbeit, R. D. (1993). Application of pulsed-field gel electrophoresis to molecular epidemiology. In Diagnostic Molecular Microbiology: Principles and Applications, pp. 563-572. Edited by D. H. Persing, T. F. Smith, F. C. Tenover & T. J. White. Washington, DC: American Society for Microbiology.
23. Morita, Y., Tomida, J. & Kawamura, Y. (2012). MexXY multidrug efflux system of Pseudomonas aeruginosa. Front Microbiol 3, 408.
24. Nakajima, A., Sugimoto, Y., Yoneyama, H. & Nakae, T. (2002). Highlevel fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation. Microbiol Immunol 46, 391-395.
25. Nemec, A., Krizova, L., Maixnerova, M. & Musilek, M. (2010). Multidrug-resistant epidemic clones among bloodstream isolates of Pseudomonas aeruginosa in the Czech Republic. Res Microbiol 161, 234-242.
26. Nicolau, D. P. (2008). Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 9, 23-37.
27. Nikaido, H. (1998). Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis 27 (Suppl 1), S32-S41.
28. Pagès, J. M., Masi, M. & Barbe, J. (2005). Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med 11, 382-389.
29. Poole, K. (2004). Efflux-mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect 10, 12-26.
30. Puig, M., Fusté, C. & Viñas, M. (1993). Outer membrane proteins from Serratia marcescens. Can J Microbiol 39, 108-111.
31. Rodriguez, N., Roig, S., Olmedo, N., Lorén, J. G. & Rius, N. (2004). A new bioassay method for quantitative analysis of tetracyclines. J Ind Microbiol Biotechnol 31, 379-383.
32. Rodríguez-Martínez, J. M., Poirel, L. & Nordmann, P. (2009). Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53, 4783-4788.
33. Ruiz-Martínez, L., Ló pez-Jiménez, L., Fusté, E., Vinuesa, T., Martínez, J. P. & Viñas, M. (2011). Class 1 integrons in environmental and clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 38, 398-402.
34. Shahcheraghi, F., Badmasti, F. & Feizabadi, M. M. (2010). Molecular characterization of class 1 integrons in MDR Pseudomonas aeruginosa isolated from clinical settings in Iran, Tehran. FEMS Immunol Med Microbiol 58, 421-425.
35. Strateva, T. & Yordanov, D. (2009). Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J Med Microbiol 58, 1133-1148.
36. Syrmis, M., Bell, S., Bye, P., Coulter, C., Harbour, C., Iredell, J., Kidd, T., O'Carroll, M., Rose, B. & other authors (2008). High prevalence of a class 1 integron-associated aadB gene cassette in Pseudomonas aeruginosa isolates from an Australian cystic fibrosis patient population. Pathology 40, 524-525.
37. Trautmann, M., Heinemann, M., Zick, R., Möricke, A., Seidelmann, M. & Berger, D. (1998). Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Eur J Clin Microbiol Infect Dis 17, 754-760.
38. Veiga-Crespo, P., Fusté, E., Vinuesa, T., Viñas, M. & Villa, T. G. (2011). Synergism between outer membrane proteins and antimicrobials. Antimicrob Agents Chemother 55, 2206-2211.
39. Weiss, D. S., Chen, J. C., Ghigo, J. M., Boyd, D. & Beckwith, J. (1999). Localization of FtsI (PBP3) to the septal ring requires its membrane anchor, the Z ring, FtsA, FtsQ, and FtsL. J Bacteriol 181, 508-520.
40. Woodford, N., Turton, J. F. & Livermore, D. M. (2011). Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 35, 736-755.